Arcadia Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Arcadia Biosciences şirketinin toplam hissedar öz sermayesi $11.6M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $17.4M ve $5.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$8.11m
Eşitlik	US$11.57m
Toplam yükümlülükler	US$5.80m
Toplam varlıklar	US$17.37m

Son finansal sağlık güncellemeleri

We're Hopeful That Arcadia Biosciences (NASDAQ:RKDA) Will Use Its Cash Wisely

Mar 01

Recent updates

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Nov 22

The Future Looks Bright For Arcadia Biosciences

Dec 01

Arcadia Biosciences EPS misses by $0.06

Nov 12

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: RKDA 'nin kısa vadeli varlıkları ( $12.4M ) kısa vadeli yükümlülüklerini ( $2.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: RKDA şirketinin kısa vadeli varlıkları ( $12.4M ) uzun vadeli yükümlülüklerini ( $3.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: RKDA borçsuzdur.

Borcun Azaltılması: RKDA un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: RKDA şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 1.8 oranında tarihsel oranda büyümeye devam ederse RKDA un bir yıldan az nakit akışı süresi vardır.

Arcadia Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're Hopeful That Arcadia Biosciences (NASDAQ:RKDA) Will Use Its Cash Wisely

Arcadia Biosciences Receives Non-Compliance Letter from Nasdaq

Recent updates

Arcadia Biosciences, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Consensus EPS estimates fall by 27%, revenue upgraded

Consensus estimates of losses per share improve by 17%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Arcadia Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Arcadia Biosciences, Inc. Announces Appointment of Mark Kawakami, as Chief Financial Officer

Consensus revenue estimates decrease by 17%, EPS upgraded

Arcadia Biosciences, Inc., Annual General Meeting, Jun 25, 2024

First quarter 2024 earnings released: US$1.78 loss per share (vs US$10.86 loss in 1Q 2023)

First quarter 2024 earnings released: US$1.78 loss per share (vs US$10.86 loss in 1Q 2023)

Arcadia Biosciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 27%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Arcadia Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Insufficient new directors

Arcadia Biosciences, Inc. (Rkda) Expands Goodwheat™ Mac & Cheese with Nationwide Availability

Arcadia Biosciences, Inc. Announces the Resignation of Laura Pitlik as Chief Marketing Officer

Consensus EPS estimates fall by 31%

Consensus EPS estimates upgraded to US$7.44 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Consensus revenue estimates increase by 13%, EPS downgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Arcadia Biosciences, Inc. Launches Goodwheat into the Breakfast Category with New Better-For-You Pancake & Waffle Mixes and Single-Serve Quikcakes

First quarter 2023 earnings released: US$10.86 loss per share (vs US$8.09 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Arcadia Biosciences (NASDAQ:RKDA) Will Use Its Cash Wisely

Arcadia Biosciences, Inc. Announces CFO Changes

Consensus forecasts updated

Price target decreased to US$2.50

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences Receives Non-Compliance Letter from Nasdaq

Arcadia Biosciences to raise $5M in securities offering

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$3.75

Arcadia Biosciences, Inc., Annual General Meeting, Jun 01, 2022

Consensus revenue estimates fall by 45%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Arcadia Biosciences, Inc. Announces Executive Changes

Investor sentiment improved over the past week

Price target decreased to US$5.25

Chief Growth Officer Chris Cuvelier has left the company

Arcadia Biosciences: Market Still Unconvinced Of Its Health Offerings

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: US$0.098 loss per share (vs US$0.60 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$1.04 loss in 2Q 2020)

Consensus EPS estimates increase to -US$0.81

Price target increased to US$5.75

Consensus revenue estimates increase to US$8.87m

Arcadia Biosciences, Inc. (NasdaqCM:RKDA) acquired Assets of Lief Holdings, LLC and Live Zola, LLC. from Lief Holdings, LLC and Live Zola, LLC for $6.1 million.

Consensus forecasts updated

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.53 loss in FY 2019)

Price target raised to US$7.53

Arcadia Biosciences, Inc. Expands GoodWheat™ Patent Portfolio

Arcadia Biosciences Welcomes Debbie Carosella to Board Of Directors

New 90-day high: US$3.58

Arcadia Biosciences, Inc. announced that it expects to receive $25.146633 million in funding

New 90-day high: US$3.45

Arcadia Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $7.672668 million.

Price target lowered to US$9.33

New 90-day low: US$2.53

Analysts update estimates